Please login to the form below

Not currently logged in
Email:
Password:

Inviragen

This page shows the latest Inviragen news and features for those working in and with pharma, biotech and healthcare.

Sanofi's dengue vaccine could debut in 2015

Sanofi's dengue vaccine could debut in 2015

Takeda is also developing a vaccine against dengue fever that was acquired along with other candidates when it took over Inviragen last year in a deal valued at up to $250m.

Latest news

  • Takeda buys vaccines specialist Inviragen Takeda buys vaccines specialist Inviragen

    Takeda buys vaccines specialist Inviragen. Acquires vaccine candidates against dengue fever and hand, foot and mouth disease in $250m deal. ... The biopharma company Inviragen, which has operations in the US and Singapore, will receive an upfront payment

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch table for May 2013 Deal Watch table for May 2013

    UAE based regional company $40m $244m option for 52%. 284. Inviragen/ Takeda.

  • Pharma deals during May 2013 Pharma deals during May 2013

    targets from Abide; Takeda's $250m acquisition of Inviragen; GSK's $325m acquisition of the vaccine platform technology company, Okairos; and BMS's $112m licence for antibody conjugates from Ambrx.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics